WVC Presentation

World  Vaccine Conference presentation: 

Seneca's primary asset, SVV-001, is an oncolytic virus that selectively replicates in tumor cells expressing the TEM8 receptor, while being non-pathogenic in both humans and animals. Extensively evaluated in over 30 preclinical cancer models and three clinical trials for solid cancers including neuroendocrine and pediatric tumors. Combining SVV-001 with immune modulators, cytokines, and checkpoint inhibitors has shown synergistic anti-tumor effects in various animal studies. 

Minute 0:00 : Story of Discovery of SVV

1:22 – High specificity of Seneca Valley Virus
3:43 – SVV clinical experience
6:35 – specificity of SVV in tumors 
7:31 – Binding of SVV to TEM8 receptor
8:25 – Tem8 is highly expressed in cancer cells but not in normal cells
10:05 – Tem8 is associated with bad prognosis
10:26 – Patient Screening Assay (Companion Diagnostic) to replication of SVV
11:57 – SVV in combination with CPIs
14:45 – SVV turns cold to hot tumors
15:25 – Summary of upcoming clinical trial
18:05 – Armed SVV program summary
20:27 – Conclusions